Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. Vaccination is generally accepted as the most effective strategy for influenza prevention. While current influenza vaccines are effective, they still have...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1381508/full |
| _version_ | 1797205903000207360 |
|---|---|
| author | Elena P. Mazunina Vladimir A. Gushchin Vladimir A. Gushchin Vladimir A. Gushchin Denis A. Kleymenov Andrei E. Siniavin Andrei E. Siniavin Elena I. Burtseva Maksim M. Shmarov Evgenya A. Mukasheva Evgeniia N. Bykonia Sofia R. Kozlova Elina A. Evgrafova Anastasia N. Zolotar Elena V. Shidlovskaya Elena S. Kirillova Anastasiya S. Krepkaia Evgeny V. Usachev Nadezhda A. Kuznetsova Igor A. Ivanov Igor A. Ivanov Sergey E. Dmitriev Sergey E. Dmitriev Sergey E. Dmitriev Roman A. Ivanov Denis Y. Logunov Alexander L. Gintsburg Alexander L. Gintsburg |
| author_facet | Elena P. Mazunina Vladimir A. Gushchin Vladimir A. Gushchin Vladimir A. Gushchin Denis A. Kleymenov Andrei E. Siniavin Andrei E. Siniavin Elena I. Burtseva Maksim M. Shmarov Evgenya A. Mukasheva Evgeniia N. Bykonia Sofia R. Kozlova Elina A. Evgrafova Anastasia N. Zolotar Elena V. Shidlovskaya Elena S. Kirillova Anastasiya S. Krepkaia Evgeny V. Usachev Nadezhda A. Kuznetsova Igor A. Ivanov Igor A. Ivanov Sergey E. Dmitriev Sergey E. Dmitriev Sergey E. Dmitriev Roman A. Ivanov Denis Y. Logunov Alexander L. Gintsburg Alexander L. Gintsburg |
| author_sort | Elena P. Mazunina |
| collection | DOAJ |
| description | Seasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. Vaccination is generally accepted as the most effective strategy for influenza prevention. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidate, evaluate its immunogenicity using the hemagglutination inhibition assay, ELISA, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidate compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks. |
| first_indexed | 2024-04-24T08:58:30Z |
| format | Article |
| id | doaj.art-5436628e6d8743ce9fa3eedb426fd822 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T08:58:30Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5436628e6d8743ce9fa3eedb426fd8222024-04-16T05:00:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.13815081381508Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune responseElena P. Mazunina0Vladimir A. Gushchin1Vladimir A. Gushchin2Vladimir A. Gushchin3Denis A. Kleymenov4Andrei E. Siniavin5Andrei E. Siniavin6Elena I. Burtseva7Maksim M. Shmarov8Evgenya A. Mukasheva9Evgeniia N. Bykonia10Sofia R. Kozlova11Elina A. Evgrafova12Anastasia N. Zolotar13Elena V. Shidlovskaya14Elena S. Kirillova15Anastasiya S. Krepkaia16Evgeny V. Usachev17Nadezhda A. Kuznetsova18Igor A. Ivanov19Igor A. Ivanov20Sergey E. Dmitriev21Sergey E. Dmitriev22Sergey E. Dmitriev23Roman A. Ivanov24Denis Y. Logunov25Alexander L. Gintsburg26Alexander L. Gintsburg27Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaDepartment of Virology, Lomonosov Moscow State University, Moscow, RussiaDepartment of Medical Genetics, I. M. Sechenov First Moscow State Medical University, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, RussiaFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, RussiaTranslational Medicine Research Center, Sirius University of Science and Technology, Sochi, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaFederal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, RussiaInfectiology Department, I. M. Sechenov First Moscow State Medical University, Moscow, RussiaSeasonal influenza remains a serious global health problem, leading to high mortality rates among the elderly and individuals with comorbidities. Vaccination is generally accepted as the most effective strategy for influenza prevention. While current influenza vaccines are effective, they still have limitations, including narrow specificity for certain serological variants, which may result in a mismatch between vaccine antigens and circulating strains. Additionally, the rapid variability of the virus poses challenges in providing extended protection beyond a single season. Therefore, mRNA technology is particularly promising for influenza prevention, as it enables the rapid development of multivalent vaccines and allows for quick updates of their antigenic composition. mRNA vaccines have already proven successful in preventing COVID-19 by eliciting rapid cellular and humoral immune responses. In this study, we present the development of a trivalent mRNA vaccine candidate, evaluate its immunogenicity using the hemagglutination inhibition assay, ELISA, and assess its efficacy in animals. We demonstrate the higher immunogenicity of the mRNA vaccine candidate compared to the inactivated split influenza vaccine and its enhanced ability to generate a cross-specific humoral immune response. These findings highlight the potential mRNA technology in overcoming current limitations of influenza vaccines and hold promise for ensuring greater efficacy in preventing seasonal influenza outbreaks.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1381508/fullseasonal influenzavaccinemRNAimmunogenicityefficacyimmune response |
| spellingShingle | Elena P. Mazunina Vladimir A. Gushchin Vladimir A. Gushchin Vladimir A. Gushchin Denis A. Kleymenov Andrei E. Siniavin Andrei E. Siniavin Elena I. Burtseva Maksim M. Shmarov Evgenya A. Mukasheva Evgeniia N. Bykonia Sofia R. Kozlova Elina A. Evgrafova Anastasia N. Zolotar Elena V. Shidlovskaya Elena S. Kirillova Anastasiya S. Krepkaia Evgeny V. Usachev Nadezhda A. Kuznetsova Igor A. Ivanov Igor A. Ivanov Sergey E. Dmitriev Sergey E. Dmitriev Sergey E. Dmitriev Roman A. Ivanov Denis Y. Logunov Alexander L. Gintsburg Alexander L. Gintsburg Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response Frontiers in Immunology seasonal influenza vaccine mRNA immunogenicity efficacy immune response |
| title | Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response |
| title_full | Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response |
| title_fullStr | Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response |
| title_full_unstemmed | Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response |
| title_short | Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response |
| title_sort | trivalent mrna vaccine candidate against seasonal flu with cross specific humoral immune response |
| topic | seasonal influenza vaccine mRNA immunogenicity efficacy immune response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1381508/full |
| work_keys_str_mv | AT elenapmazunina trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT vladimiragushchin trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT vladimiragushchin trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT vladimiragushchin trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT denisakleymenov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT andreiesiniavin trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT andreiesiniavin trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT elenaiburtseva trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT maksimmshmarov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT evgenyaamukasheva trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT evgeniianbykonia trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT sofiarkozlova trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT elinaaevgrafova trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT anastasianzolotar trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT elenavshidlovskaya trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT elenaskirillova trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT anastasiyaskrepkaia trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT evgenyvusachev trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT nadezhdaakuznetsova trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT igoraivanov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT igoraivanov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT sergeyedmitriev trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT sergeyedmitriev trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT sergeyedmitriev trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT romanaivanov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT denisylogunov trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT alexanderlgintsburg trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse AT alexanderlgintsburg trivalentmrnavaccinecandidateagainstseasonalfluwithcrossspecifichumoralimmuneresponse |